New York, NY, and Tel Aviv, ISRAEL, Sept. 30, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, right now introduced that it has obtained two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for patent functions masking the Company’s Total Biochemical Infrared Analysis (TBIA) Fourier Transformed Infrared (FTIR) pan-cancer blood diagnostics platform. The Notices of Allowance are for patent functions entitled 1) “Infrared (IR) Spectroscopy System” and a couple of) “Infrared Analysis of Benign Tumors.” The Company has already obtained CE marks for its TBIA blood diagnostic check in breast most cancers and colon most cancers.
The key allowed declare for Infrared (IR) Spectroscopy System patent software was surrounding the system of gathering blood, acquiring FTIR spectrum from peripheral blood lymphocytes, and an output unit, configured to generate an output indicative of the presence of a strong tumor. The declare allowed for the patent software Analysis of Benign Tumors was associated to the mandatory circumstances to seize constant information to yield actionable outcomes.
“The allowance of these two seminal pieces of intellectual property underlying the Company’s TBIA FTIR pan-cancer diagnosis platform, which we believe will ultimately outcompete the liquid biopsy platform for routine testing of asymptomatic and early-stage cancer patients, including tests such as Illumina’s Galleri®,” stated Gerald Commissiong, President & CEO of Todos Medical. “As we prepare to launch our Videssa breast cancer test in 2023, it will be very important to capture TBIA FTIR data from each patient tested with Videssa so we can continue to build the TBIA FTIR algorithm in order to gather sufficient data to submit to FDA. This platform will allow us to test for multiple cancers from the same blood sample because of the power of spectroscopy, as compared with more traditional antibody-based assays that make multiplexing challenging. We are very excited to be able to allow this technology to mature appropriately while we launch Videssa in the market.”
The international most cancers diagnostics market measurement is predicted to be enhance to roughly USD $258 billion by 2030 from USD $124 billion in 2021, in keeping with Precedence Research. The international most cancers diagnostics market is predicted to expertise progress at a CAGR of 8.4% over the forecast interval 2022 to 2030.
About Todos Medical Ltd.
Founded in Rehovot, Israel with places of work in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic options for the early detection of a range of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening expertise utilizing peripheral blood evaluation that examines most cancers’s affect on the immune system, on the lookout for biochemical modifications in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening exams, TMB-1 and TMB-2 have obtained a CE mark in Europe. Todos just lately acquired U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to achieve rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab at the moment performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast most cancers blood check. More data on Provista is out there at www.provistadx.com.
Todos can be creating blood exams for the early detection of neurodegenerative problems, equivalent to Alzheimer’s illness. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood check that determines the power of peripheral blood lymphocytes (PBLs) and monocytes to resist an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that sure illnesses, most notably Alzheimer’s illness, are the end result of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive within the use of peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a typical relationship between PBLs and neurons within the mind.
Todos fashioned the Israeli-based majority-owned three way partnership 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the mental property surrounding 3CL protease–primarily based diagnostic testing and growth of 3CL protease botanical and pharmaceutical inhibitors that focus on a elementary reproductive mechanism of coronaviruses. 3CL Pharma, by Todos’ model, has commercialized the 3CL protease inhibitor immune assist dietary complement Tollovid™ within the United States, is creating the twin mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, whereas additionally creating the 3CL protease diagnostic TolloTest™.
To buy Tollovid please go to Amazon or www.MyTollovid.com. For extra data, please go to https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained on this press launch could represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated scientific growth applications and scientific trials. These forward-looking statements are primarily based solely on present expectations of administration, and are topic to important dangers and uncertainties that might trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, price, and outcomes of scientific trials and product growth applications; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our skill to acquire extra funding required to conduct our analysis, growth and commercialization actions. In addition, the next components, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: modifications in expertise and market necessities; delays or obstacles in launching our scientific trials; modifications in laws; incapacity to well timed develop and introduce new applied sciences, merchandise and functions; lack of validation of our expertise as we progress additional and lack of acceptance of our strategies by the scientific group; incapacity to retain or appeal to key staff whose data is important to the event of our merchandise; unexpected scientific difficulties which will develop with our course of; better price of ultimate product than anticipated; loss of market share and stress on pricing ensuing from the competitors; and laboratory outcomes that don’t translate to equally good leads to actual settings, all of which may trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Except as in any other case required by legislation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please check with its experiences filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch CFO
Todos Medical
917-983-4229 x 104
[email protected]
Todos Press Contact:
Giancarlo Greager
TreviPR
702-768-1906
[email protected]
